Skip to main content
Clinical Trials/NCT00959023
NCT00959023
Unknown
N/A

UK Genetic Prostate Cancer Study

Institute of Cancer Research, United Kingdom135 sites in 1 country21,000 target enrollmentJune 1993
ConditionsProstate Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Institute of Cancer Research, United Kingdom
Enrollment
21000
Locations
135
Primary Endpoint
Prostate cancer (PC) predisposition (PCP) genes
Last Updated
12 years ago

Overview

Brief Summary

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify genes related to cancer.

PURPOSE: This clinical trial is studying blood and tumor samples from men with an inherited risk of prostate cancer.

Detailed Description

OBJECTIVES: * To find genes that predispose to prostate cancer (using genetic linkage and other molecular biology techniques). * To determine if genes that predispose to prostate cancer are associated with disease and treatment parameters. * To determine if genes that predispose to prostate cancer are associated with environmental factors. * To estimate the percentage of prostate cancer patients who have a positive family history of the disease. * To estimate the relative risk of developing prostate cancer in a currently unaffected member of a prostate cancer family. * To ascertain whether relatives of prostate cancer patients are at increased risk of developing cancers other than prostate cancer. * To build up a large blood and tumor (both fresh and preserved) bank from patients with prostate cancer to identify prostate cancer predisposition gene(s), determine the prevalence and penetrance of prostate cancer predisposition genes in prostate cancer patients, correlate changes in prostate cancer predisposition gene(s) with disease and treatment parameters by matching with clinical data from clinical databases already held as part of the medical record on these patients, and correlate changes in prostate cancer predisposition gene(s) with environmental factors collected by questionnaire from these patients. * To use the blood and tumor bank for marker studies (DNA, RNA, serum, plasma, protein, and other molecules) to define the role of these markers in disease prediction and progression. * To develop microarrays from prostate cancers to determine their genetic profile and correlate this with prostate cancer genetic predisposition genes. * To collect tissue from other unaffected and affected members of the family in cases where a genetic alteration is found, in order to ascertain whether this alteration is associated with disease risk. * To collect tissue samples from unaffected family members who show an interest in taking part in the study. OUTLINE: Patients are assessed by a family history and epidemiology questionnaire and undergo a medical record review. Patients and relatives with prostate cancer may undergo blood sample collection for genetic analysis of prostate cancer predisposition genes and measurement of markers of associations with genetic changes associated with prostate cancer. Blood and tumor samples are stored for future studies.

Registry
clinicaltrials.gov
Start Date
June 1993
End Date
TBD
Last Updated
12 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Institute of Cancer Research, United Kingdom

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Prostate cancer (PC) predisposition (PCP) genes

Secondary Outcomes

  • Family history of PC
  • Association of PCP genes with disease and treatment parameters
  • Association of PCP with environmental factors
  • Relative risk of developing PC
  • Increased risk relatives of PC patients are to develop cancers other than PC
  • Markers of PC that are associated with PCP genes
  • Specific tumor genetic profile correlated with PCP genes

Study Sites (135)

Loading locations...

Similar Trials